DR. MELISSA LYNN MCKERNAN PULLIAM M.D.
Prescription History 1053388694
Internal Medicine - Clinical Cardiac Electrophysiology in Lancaster, PA

NPI Status: Active since March 02, 2006

Contact Information

217 HARRISBURG AVE
THE HEART GROUP OF LGHEALTH
LANCASTER, PA
ZIP 17603
Phone: (717) 544-8300
Fax: (717) 544-8265

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MELISSA LYNN MCKERNAN PULLIAM M.D., an active Clinical Cardiac Electrophysiology specialist practicing in Lancaster, PA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 95 documented patient claims. Among these therapy options, the most frequently utilized medication is Metoprolol Succinate, which accounts for 36 claims alone.

Medication Index


Eliquis

Generic Formulation: ApixabanSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 12
30-Day Fills 20.0
Days Supply 600
PA State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills137.0
Peer Average Days Supply3,769
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.0% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,804.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$983.68

State Avg Cost Per Claim

$730.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Isosorbide Mononitrate Er

Generic Formulation: Isosorbide MononitrateSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 21
30-Day Fills 29.0
Days Supply 870
PA State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills82.6
Peer Average Days Supply2,401
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $164.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.85

State Avg Cost Per Claim

$18.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease). This medication belongs to a class of drugs known as nitrates. It works by relaxing and widening blood vessels so blood can flow more easily to the heart. This medication will not relieve chest pain once it occurs. Also, it is not intended to be taken just before physical activities (such as exercise or sexual intercourse) to prevent chest pain. Other medications may be prescribed by your doctor for these conditions. Consult your doctor for more details.

Lisinopril

Generic Formulation: LisinoprilSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 11
30-Day Fills 18.0
Days Supply 540
PA State Average Benchmarks
Peer Average Claims135.0
Peer Average 30-Day Fills316.7
Peer Average Days Supply9,352
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 91.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $90.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.26

State Avg Cost Per Claim

$8.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Therapeutic Applications

Lisinopril is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat heart failure and to improve survival after a heart attack. Lisinopril belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily.

Metoprolol Succinate

Generic Formulation: Metoprolol SuccinateSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 36
30-Day Fills 60.0
Days Supply 1,800
PA State Average Benchmarks
Peer Average Claims118.0
Peer Average 30-Day Fills263.3
Peer Average Days Supply7,751
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.5% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $515.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.31

State Avg Cost Per Claim

$19.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Therapeutic Applications

This medication is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart.

Metoprolol Tartrate

Generic Formulation: Metoprolol TartrateSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 15
30-Day Fills 23.0
Days Supply 526
PA State Average Benchmarks
Peer Average Claims86.0
Peer Average 30-Day Fills177.5
Peer Average Days Supply5,153
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.6% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $81.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.43

State Avg Cost Per Claim

$8.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Therapeutic Applications

Metoprolol is used with or without other medications to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to treat chest pain (angina) and to improve survival after a heart attack. Metoprolol belongs to a class of drugs known as beta blockers. It works by blocking the action of certain natural chemicals in your body, such as epinephrine, on the heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the heart.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MELISSA LYNN MCKERNAN PULLIAM M.D. provides transparency into local medical care patterns within Lancaster, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Clinical Cardiac Electrophysiology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.